Results 21 to 30 of about 655,557 (182)

Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination

Acta Neuropathologica Communications, 2023
Bruton’s tyrosine kinase (BTK) is an emerging target in multiple sclerosis (MS). Alongside its role in B cell receptor signaling and B cell development, BTK regulates myeloid cell activation and inflammatory responses. Here we demonstrate efficacy of BTK
Kirsten Scarlett Evonuk, Sen Wang, Josh Mattie, C. J. Cracchiolo, Reine Mager, Željko Ferenčić, Ethan Sprague, Brandon Carrier, Kai Schofield, Evelyn Martinez, Zachary Stewart, Tara Petrosino, Gregory Andrew Johnson, Isharat Yusuf, Warren Plaisted, Zachary Naiman, Timothy Delp, Laura Carter, Suzana Marušić   +18 more
doaj   +1 more source

Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations

Molecules, 2022
Bruton’s tyrosine kinase (BTK) is a key protein from the TEC family and is involved in B-cell lymphoma occurrence and development. Targeting BTK is therefore an effective strategy for B-cell lymphoma treatment.
Xiangfan Yu, Simei Qiu, Dongshan Sun, Pei Guo, Quhuan Li   +4 more
doaj   +1 more source

Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder

Journal of Neuroinflammation, 2023
Background Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory autoimmune disease of the central nervous system that involves B-cell receptor signaling as well as astrocyte–microglia interaction, which both contribute to evolution of NMOSD ...
Ye Liu, Zhenning Huang, Tian-Xiang Zhang, Bin Han, Guili Yang, Dongmei Jia, Li Yang, Qiang Liu, Alexander Y. L. Lau, Friedemann Paul, Alexei Verkhratsky, Fu-Dong Shi, Chao Zhang   +12 more
doaj   +1 more source

SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation

Cancer Biology & Medicine, 2022
Objective: B-cell antigen receptor (BCR) signaling is required to maintain the physiological functions of normal B cells and plays an important pathogenic role in B-cell malignancies. Bruton tyrosine kinase (BTK), a critical mediator of BCR signaling, is
Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang, Binghui Li   +7 more
doaj   +1 more source

Infographic - BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor na¨ıve mantle cell lymphoma

, 2022
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor na¨ıve mantle cell lymphoma ...
Christopher Chay (14122335), Yuqin Song (690119), Michael L Wang (14122353), Wojciech Jurczak (7872608), Hannah M Messersmith (14122341), Nirav N Shah (14122326), Chan Y Cheah (14122329), Martin Dreyling (260055), Mitul Gandhi (14122332), Toby A Eyre (8206989), Rodrigo Ito (14122350), Yucai Wang (513301), Amy S Ruppert (14122344), Jeff Sharman (3843502), Valerie A Muthig (14122347), David J Andorsky (14122338)   +15 more
core   +1 more source

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Frontiers in Pharmacology, 2022
Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population.
Weam Othman Elbezanti, Weam Othman Elbezanti, Omar S. Al-Odat, Omar S. Al-Odat, Robert Chitren, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey   +14 more
doaj   +1 more source

Current approach to Waldenström Macroglobulinemia

Cancer Treatment and Research Communications, 2022
Waldenström Macroglobulinemia (WM) is a unique, low grade, IgM lymphoplasmacytic lymphoma with a heterogeneous clinical course. A paucity of high-grade evidence from large phase 3 trials remains a major issue in the field despite a rapidly expanding ...
Gayathri Ravi, Prashant Kapoor
doaj   +1 more source

The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells

, 2008
Activated mast cells are a major source of the eicosanoids PGD(2) and leukotriene C(4) (LTC(4)), which contribute to allergic responses. These eicosanoids are produced following the ERK1/2-dependent activation of cytosolic phospholipase A(2), thus ...
Gilfillan, Alasdair M., Kuehn, Hye Sun, Beaven, Michael A., Swindle, Emily J., Kim, Mi-Sun, Metcalfe, Dean D.   +5 more
core   +2 more sources

Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation

eJHaem, 2022
Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor‐treatment naïve patients.
Lone Schejbel, Marie Fredslund Breinholt, Anne Ortved Gang, Torsten Holm Nielsen, Lars Møller Pedersen, Estrid Høgdall, Peter Nørgaard   +6 more
doaj   +1 more source

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Journal of Hematology & Oncology, 2021
B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib,
Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach, Erin Hertlein   +13 more
doaj   +1 more source